Shenzhen Mindray Bio-Medical Electronics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Hao Wu

İcra Kurulu Başkanı

CN¥22.6m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

We Like Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) Returns And Here's How They're Trending

Nov 18

Is There An Opportunity With Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) 27% Undervaluation?

Oct 24

Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Ticks All The Boxes When It Comes To Earnings Growth

Oct 08

Risks To Shareholder Returns Are Elevated At These Prices For Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760)

Aug 12

Shareholders Would Enjoy A Repeat Of Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) Recent Growth In Returns

Jul 28

Estimating The Fair Value Of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760)

Jun 06

These 4 Measures Indicate That Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Is Using Debt Safely

May 21

Analysts Have Made A Financial Statement On Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) First-Quarter Report

Apr 30

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) Share Price Not Quite Adding Up

Apr 21

Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Looks To Prolong Its Impressive Returns

Apr 02

CEO

Hao Wu (52 yo)

7.8yrs

Görev süresi

CN¥22,623,200

Tazminat

Mr. Hao Wu serves as Managing Director of Shenzhen Mindray Bio-Medical Electronics Co., Ltd and has been its Director since January 05, 2017 and was its Executive Deputy General Manager. Mr. Wu graduated f...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hao Wu	MD & Director	7.8yrs	CN¥22.62m	Veri yok
Yanmei Guo	Executive Deputy GM & Director	7.8yrs	CN¥13.32m	Veri yok
Xiting Li	Chairman	7.8yrs	CN¥26.63m	27.04% CN¥ 86.1b
Hang Xu	Director & Chairman of Mindray Medical International Ltd	33.8yrs	Veri yok	24.55% CN¥ 78.2b
Cheng Minghe	Vice Chairman of the Board	7.8yrs	CN¥5.04m	4.26% CN¥ 13.6b
Zhi Tang	Chairman of the Supervisory Board	7.8yrs	Veri yok	Veri yok
Qiang Ji	Non-Employee Supervisor	5yrs	Veri yok	Veri yok
Huming Liang	Independent Director	3.5yrs	CN¥400.00k	0.00011% CN¥ 350.3k
Shanrong Hu	Independent Director	1.5yrs	CN¥233.30k	Veri yok
Xianyi Zhou	Independent Director	1.5yrs	CN¥233.30k	Veri yok
Shengping Gao	Independent Director	1.5yrs	CN¥233.30k	Veri yok
Jing Xu	Independent Director	1.5yrs	CN¥233.30k	Veri yok

6.4yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300760 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Shenzhen Mindray Bio-Medical Electronics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 17, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 10, 2022

Recent updates

We Like Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) Returns And Here's How They're Trending

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) 27% Undervaluation?

Investor sentiment deteriorates as stock falls 17%

Now 24% undervalued after recent price drop

Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Ticks All The Boxes When It Comes To Earnings Growth

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Proposes Interim Dividend for the First Half of 2024

Risks To Shareholder Returns Are Elevated At These Prices For Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760)

Shareholders Would Enjoy A Repeat Of Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) Recent Growth In Returns

Estimating The Fair Value Of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760)

Now 21% undervalued

Dividend of CN¥1.50 announced

These 4 Measures Indicate That Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Is Using Debt Safely

Analysts Have Made A Financial Statement On Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) First-Quarter Report

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 17, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) Share Price Not Quite Adding Up

Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Looks To Prolong Its Impressive Returns

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Now 20% undervalued after recent price drop

Now 20% undervalued

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Implements Profit Distribution for Third Quarter of 2023, Payable on 22 November 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Approves Profit Distribution Plan for Third Quarter 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Proposes Third Quarterly Dividend

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to Report Q3, 2023 Results on Oct 30, 2023

Price target decreased by 8.1% to CN¥402

Second quarter 2023 earnings: EPS exceeds analyst expectations

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Approves Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥7.94 (vs CN¥6.59 in FY 2021)

Mindray Revolutionizes the Way of Using Ultrasound with TE Air, Its First Wireless Handheld Ultrasound System

Mindray Introduces New Wearable Patient Monitoring System, Refining Clinician’s Workflow to Track Patient Conditions

Less than half of directors are independent

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations

Mindray Reimagines Point of Care Systems with Launch of New TEX20 Diagnostic Ultrasound Series At Euroanaesthesia 2022

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 19 May 2022

Less than half of directors are independent

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Annual General Meeting, May 10, 2022

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Proposes Final Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) announces an Equity Buyback for CNY 1,000 million worth of its shares.

Third quarter 2021 earnings released: EPS CN¥1.91 (vs CN¥1.57 in 3Q 2020)

Mindray Launches New MC-80 Automated Digital Cell Morphology Analyzer, Taking Morphology Analysis to the Next Level

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) completed the acquisition of HyTest Ltd. from Summa Equity.

Investor sentiment improved over the past week

Mindray Announces the Launch of its Latest Point-Of-Care (POC) Ultrasound System, the TE9

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) announces an Equity Buyback for CNY 1,000 million worth of its shares.

Price target decreased to CN¥489

Second quarter 2021 earnings released: EPS CN¥2.16 (vs CN¥1.76 in 2Q 2020)

Investor sentiment deteriorated over the past week

Mindray Unveils Nuewa I9, A New Ob/GYN Diagnostic Ultrasound System

Mindray Launches Resona I9 Ultrasound System, Revolutionizing General Imaging

Mindray Defines Future of Imaging Technologies with New General Imaging, Women's Healthcare and Cardiology Ultrasound Solutions

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Approves Cash Dividend for the Year 2020, Payable on 28 May 2021

Price target increased to CN¥502

First quarter 2021 earnings released: EPS CN¥1.41 (vs CN¥1.08 in 1Q 2020)

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Proposes Final Dividend for the Year 2020

Price target increased to CN¥480

Investor sentiment deteriorated over the past week

New 90-day high: CN¥492

Mindray Launches New BeneFusion e Series Infusion Systems, Delivering Efficiency in Every Droplet

Mindray Transforms Spot Check Patient Monitoring with New VS Series Vital Signs Monitors

New 90-day high: CN¥478